Mirum Pharmaceuticals (MIRM) Cash from Financing Activities (2019 - 2026)

Mirum Pharmaceuticals' Cash from Financing Activities history runs 8 years deep, the most recent figure standing at $270.1 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 4147.19% year-over-year to $270.1 million; the TTM figure through Mar 2026 stood at $303.9 million (up 1229.64% YoY), while the FY2025 annual figure was $40.1 million, up 126.8% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $270.1 million, up from $9.0 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $270.1 million in Q1 2026, with the low at -$329000.0 in Q4 2022.
• The 5-year median for Cash from Financing Activities is $8.7 million (2025), against an average of $45.5 million.
• Peak annual rise in Cash from Financing Activities reached 24846.67% in 2022, while the deepest fall reached 153.5% in 2022.
• Mirum Pharmaceuticals' Cash from Financing Activities stood at -$329000.0 in 2022, then surged by 640.12% to $1.8 million in 2023, then soared by 200.51% to $5.3 million in 2024, then jumped by 68.52% to $9.0 million in 2025, then jumped by 2901.21% to $270.1 million in 2026.
• Business Quant data shows MIRM's Cash from Financing Activities at $270.1 million in Q1 2026, $9.0 million in Q4 2025, and $16.1 million in Q3 2025.